p53 Antibody [CTA53-1] | 33-870

p53 Antibody [CTA53-1] | 33-870 | Gentaur UK, US & Europe Distribution

Host: Mouse

Reactivity: Human

Homology: N/A

Immunogen: Human recombinant protein was used as the immunogen for this p53 antibody.

Research Area: Cancer, Cell Cycle, Signal Transduction,

Tested Application: WB, IHC, IF

Application: Immunofluorescence: 1-2 ug/ml
Western blot: 1-2 ug/ml
IHC (FFPE) : 1-2 ug/ml for 30 minutes at RT (1)
Prediluted format : incubate for 30 min at RT (2)
Titering of the p53 antibody may be required for optimal performance.

1. FFPE testing requires sections to be boiled in pH6 10mM citrate buffer for 10-20 minutes, followed by cooling at RT for 20 minutes, prior to staining.
2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required) , drip mAb solution onto the tissue section and incubate at RT for 30 min.

Specificiy: N/A

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: Protein G affinity chromatography

Clonality: Monoclonal

Clone: CTA53-1

Isotype: IgG2a

Conjugate: Unconjugated

Physical State: Liquid

Buffer: PBS with 0.1 mg/ml BSA and 0.05% sodium azide

Concentration: 0.2 mg/mL

Storage Condition: Aliquot and Store at 2-8˚C. Avoid freez-thaw cycles.

Alternate Name: Cellular tumor antigen p53, Antigen NY-CO-13, Phosphoprotein p53, Tumor suppressor p53, TP53, P53

User Note: Optimal dilutions for each application to be determined by the researcher

BACKGROUND: This gene encodes a tumor suppressor protein containing transcriptional activation, DNA binding, and oligomerization domains. The encoded protein responds to diverse cellular stresses to regulate expression of target genes, thereby inducing cell cycle arrest, apoptosis, senescence, DNA repair, or changes in metabolism. Mutations in this gene are associated with a variety of human cancers, including hereditary cancers such as Li-Fraumeni syndrome. Alternative splicing of this gene and the use of alternate promoters result in multiple transcript variants and isoforms. Additional isoforms have also been shown to result from the use of alternate translation initiation codons. [RefSeq]